The clinical use of molecular markers as predictors of disease outcome and response to therapy in malignant melanoma

Steve R. Martinez, Hiroya Takeuchi, Dave S B Hoon

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Advances in surgical technique, diagnostic imaging, and adjuvant therapy have changed the management of melanoma patients during the last 20 yr. Despite this, several challenges remain. Attempts at using radiographic and nuclear medicine imaging to diagnose disease progression and metastatic disease at a stage early enough to affect survival have not been successful. Similarly, a reliable method of predicting or monitoring response to adjuvant therapy is currently unavailable. The last decade has seen the development of multiple RNA and DNA markers that have been applied toward the diagnosis/detection of occult disease, prediction of survival, disease surveillance, or as indicators of response to adjuvant therapy. Molecular markers may represent tumor-associated antigens, tumor suppressor genes, oncogenes, cell physiological and transcription factors, or cellular apoptotic mediators. Genomic DNA and RNA molecular markers have been applied to melanoma primary tumors, regional and visceral metastases, serum, cerebral spinal fluid, and bone marrow. The ability to use molecular markers as prognostic indicators will be invaluable as clinicians seek to stratify patients for clinical trials, adjuvant treatments, and clinical follow-up regimens.

Original languageEnglish (US)
Title of host publicationFrom Melanocytes to Melanoma: The Progression to Malignancy
PublisherHumana Press
Pages551-576
Number of pages26
ISBN (Print)1588294595, 9781588294593
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Melanoma
RNA
Survival
Nuclear Medicine
Neoplasm Antigens
Diagnostic Imaging
Therapeutics
Tumor Suppressor Genes
Genetic Markers
Oncogenes
Disease Progression
Transcription Factors
Bone Marrow
Clinical Trials
Neoplasm Metastasis
DNA
Serum
Neoplasms

Keywords

  • DNA
  • molecular markers
  • prognosis
  • RNA
  • RT-PCR
  • survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Martinez, S. R., Takeuchi, H., & Hoon, D. S. B. (2006). The clinical use of molecular markers as predictors of disease outcome and response to therapy in malignant melanoma. In From Melanocytes to Melanoma: The Progression to Malignancy (pp. 551-576). Humana Press. https://doi.org/10.1007/978-1-59259-994-3_31

The clinical use of molecular markers as predictors of disease outcome and response to therapy in malignant melanoma. / Martinez, Steve R.; Takeuchi, Hiroya; Hoon, Dave S B.

From Melanocytes to Melanoma: The Progression to Malignancy. Humana Press, 2006. p. 551-576.

Research output: Chapter in Book/Report/Conference proceedingChapter

Martinez, SR, Takeuchi, H & Hoon, DSB 2006, The clinical use of molecular markers as predictors of disease outcome and response to therapy in malignant melanoma. in From Melanocytes to Melanoma: The Progression to Malignancy. Humana Press, pp. 551-576. https://doi.org/10.1007/978-1-59259-994-3_31
Martinez SR, Takeuchi H, Hoon DSB. The clinical use of molecular markers as predictors of disease outcome and response to therapy in malignant melanoma. In From Melanocytes to Melanoma: The Progression to Malignancy. Humana Press. 2006. p. 551-576 https://doi.org/10.1007/978-1-59259-994-3_31
Martinez, Steve R. ; Takeuchi, Hiroya ; Hoon, Dave S B. / The clinical use of molecular markers as predictors of disease outcome and response to therapy in malignant melanoma. From Melanocytes to Melanoma: The Progression to Malignancy. Humana Press, 2006. pp. 551-576
@inbook{c56a0df66f12449e8b5cc1936c2e73ff,
title = "The clinical use of molecular markers as predictors of disease outcome and response to therapy in malignant melanoma",
abstract = "Advances in surgical technique, diagnostic imaging, and adjuvant therapy have changed the management of melanoma patients during the last 20 yr. Despite this, several challenges remain. Attempts at using radiographic and nuclear medicine imaging to diagnose disease progression and metastatic disease at a stage early enough to affect survival have not been successful. Similarly, a reliable method of predicting or monitoring response to adjuvant therapy is currently unavailable. The last decade has seen the development of multiple RNA and DNA markers that have been applied toward the diagnosis/detection of occult disease, prediction of survival, disease surveillance, or as indicators of response to adjuvant therapy. Molecular markers may represent tumor-associated antigens, tumor suppressor genes, oncogenes, cell physiological and transcription factors, or cellular apoptotic mediators. Genomic DNA and RNA molecular markers have been applied to melanoma primary tumors, regional and visceral metastases, serum, cerebral spinal fluid, and bone marrow. The ability to use molecular markers as prognostic indicators will be invaluable as clinicians seek to stratify patients for clinical trials, adjuvant treatments, and clinical follow-up regimens.",
keywords = "DNA, molecular markers, prognosis, RNA, RT-PCR, survival",
author = "Martinez, {Steve R.} and Hiroya Takeuchi and Hoon, {Dave S B}",
year = "2006",
doi = "10.1007/978-1-59259-994-3_31",
language = "English (US)",
isbn = "1588294595",
pages = "551--576",
booktitle = "From Melanocytes to Melanoma: The Progression to Malignancy",
publisher = "Humana Press",

}

TY - CHAP

T1 - The clinical use of molecular markers as predictors of disease outcome and response to therapy in malignant melanoma

AU - Martinez, Steve R.

AU - Takeuchi, Hiroya

AU - Hoon, Dave S B

PY - 2006

Y1 - 2006

N2 - Advances in surgical technique, diagnostic imaging, and adjuvant therapy have changed the management of melanoma patients during the last 20 yr. Despite this, several challenges remain. Attempts at using radiographic and nuclear medicine imaging to diagnose disease progression and metastatic disease at a stage early enough to affect survival have not been successful. Similarly, a reliable method of predicting or monitoring response to adjuvant therapy is currently unavailable. The last decade has seen the development of multiple RNA and DNA markers that have been applied toward the diagnosis/detection of occult disease, prediction of survival, disease surveillance, or as indicators of response to adjuvant therapy. Molecular markers may represent tumor-associated antigens, tumor suppressor genes, oncogenes, cell physiological and transcription factors, or cellular apoptotic mediators. Genomic DNA and RNA molecular markers have been applied to melanoma primary tumors, regional and visceral metastases, serum, cerebral spinal fluid, and bone marrow. The ability to use molecular markers as prognostic indicators will be invaluable as clinicians seek to stratify patients for clinical trials, adjuvant treatments, and clinical follow-up regimens.

AB - Advances in surgical technique, diagnostic imaging, and adjuvant therapy have changed the management of melanoma patients during the last 20 yr. Despite this, several challenges remain. Attempts at using radiographic and nuclear medicine imaging to diagnose disease progression and metastatic disease at a stage early enough to affect survival have not been successful. Similarly, a reliable method of predicting or monitoring response to adjuvant therapy is currently unavailable. The last decade has seen the development of multiple RNA and DNA markers that have been applied toward the diagnosis/detection of occult disease, prediction of survival, disease surveillance, or as indicators of response to adjuvant therapy. Molecular markers may represent tumor-associated antigens, tumor suppressor genes, oncogenes, cell physiological and transcription factors, or cellular apoptotic mediators. Genomic DNA and RNA molecular markers have been applied to melanoma primary tumors, regional and visceral metastases, serum, cerebral spinal fluid, and bone marrow. The ability to use molecular markers as prognostic indicators will be invaluable as clinicians seek to stratify patients for clinical trials, adjuvant treatments, and clinical follow-up regimens.

KW - DNA

KW - molecular markers

KW - prognosis

KW - RNA

KW - RT-PCR

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84891404415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891404415&partnerID=8YFLogxK

U2 - 10.1007/978-1-59259-994-3_31

DO - 10.1007/978-1-59259-994-3_31

M3 - Chapter

SN - 1588294595

SN - 9781588294593

SP - 551

EP - 576

BT - From Melanocytes to Melanoma: The Progression to Malignancy

PB - Humana Press

ER -